Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

19.95
+0.06000.30%
Post-market: 19.950.00000.00%19:30 EDT
Volume:2.56M
Turnover:51.35M
Market Cap:3.44B
PE:9.09
High:20.24
Open:20.01
Low:19.88
Close:19.89
52wk High:30.96
52wk Low:19.59
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.84
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:2.63
PE(LYR):8.67

Loading ...

Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Qiagen (QGEN) and Alcon (ALC)

TIPRANKS
·
May 07

Acadia Pharmaceuticals Q1 revenue rises on DAYBUE growth

Reuters
·
May 07

ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate

Benzinga Earnings
·
May 07

BRIEF-Acadia Pharmaceuticals Q1 EPS USD 0.02

Reuters
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 06

A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Recent Returns Send Mixed Signals

Simply Wall St.
·
May 02

Acadia R&D chief Elizabeth Thompson to retire, company launches successor search

Reuters
·
May 01

ACADIA Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.z. Thompson, Ph.d., Head of Research and Development, Following a Distinguished Career

THOMSON REUTERS
·
May 01

Earning Preview: ACADIA Pharmaceuticals this quarter’s revenue is expected to increase by 17.56%, and institutional views are bullish

Earnings Agent
·
Apr 30

Acadia Pharmaceuticals announces virtual annual shareholder meeting

Reuters
·
Apr 29

ACADIA Pharmaceuticals publishes 2025 annual report

Reuters
·
Apr 29

Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 28

Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026

Reuters
·
Apr 17

Bank of America Securities Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 16

Acadia Pharmaceuticals to report first-quarter results after US market close

Reuters
·
Apr 16

Did DAYBUE STIX’s Flexible Rett Formulation Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Simply Wall St.
·
Apr 16

A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch

Simply Wall St.
·
Apr 11

RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Apr 09

Acadia Pharmaceuticals announces Daybue Stix available in U.S.

TIPRANKS
·
Apr 07

ACADIA Pharmaceuticals Announces Daybue® Stix (Trofinetide) Is NOW Broadly Available in the United States for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Apr 07